Experimental Antibody Therapy Leads to Significant Responses in HER2-positive Breast Cancer, Phase 2 Trial Shows

Experimental Antibody Therapy Leads to Significant Responses in HER2-positive Breast Cancer, Phase 2 Trial Shows
Trastuzumab deruxtecan (DS-8201), an investigational antibody-drug conjugate developed by AstraZeneca with Daiicho Sankyo, led to clinically meaningful responses in patients with advanced HER2-positive breast cancer, a Phase 2 clinical trial shows. Trastuzumab deruxtecan is a combination of the anti-cancer HER2-targeting antibody trastuzumab (marketed under the brand name Herceptin), and an investigational cancer-killing agent called deruxtecan (a derivative of exatecan). According to findings from a previous pivotal Phase 1 trial (NCT02564900), treatment with trastuzumab deruxtecan led to unprecedented clinical activity, without significant side effects, in a group of 115 women who had been diagnosed with HER2-positive breast cancer. In this Phase 1 trial, patients had received a median of seven prior treatments, including several HER2-targeted therapies, but 60% still responded to trastuzu
Subscribe or to access all post and page content.